person · Reporting owner

PAUL STEVEN M

Disclosed activity across 7 companies

Tapewire entity: 13211
SEC CIK: 0001237564

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132	Director	April 01, 2022	April 05, 2022
ELI LILLY & CoLLY · Entity 2794	EVP, Science and Technology	December 31, 2009	February 03, 2010
Rapport Therapeutics, Inc.RAPP · Entity 4394	Director	June 10, 2026	June 10, 2026
Sage Therapeutics, Inc.SAGE · Entity 77038	Director	January 03, 2024	January 04, 2024
Seaport Therapeutics, Inc.SPTX · Entity 4799	Director	April 30, 2026	May 04, 2026
Voyager Therapeutics, Inc.VYGR · Entity 6271	Director	June 03, 2021	June 04, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date April 01, 2022 · Filed April 05, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,000	Ending reported balance After 2022-04-01 transaction · row 11 11 source rows · reconciled sequence Row 1 · 2022-04-01 · Exercise / conversion · Acquired 15,000 · Balance 16,000 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Row 2 · 2022-04-01 · Sale · Disposed 253 · Balance 15,747 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F2: Sale prices ranged from $165.91 to $166.41. Row 3 · 2022-04-01 · Sale · Disposed 4,948 · Balance 10,799 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F3: Sale prices ranged from $168.30 to $169.30. Row 4 · 2022-04-01 · Sale · Disposed 4,872 · Balance 5,927 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F4: Sale prices ranged from $169.32 to $170.28. Row 5 · 2022-04-01 · Sale · Disposed 1,235 · Balance 4,692 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F5: Sale prices ranged from $170.70 to $171.63. Row 6 · 2022-04-01 · Sale · Disposed 1,434 · Balance 3,258 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F6: Sale prices ranged from $171.75 to $172.73. Row 7 · 2022-04-01 · Sale · Disposed 642 · Balance 2,616 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F7: Sale prices ranged from $172.83 to $173.37. Row 8 · 2022-04-01 · Sale · Disposed 90 · Balance 2,526 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Row 9 · 2022-04-01 · Sale · Disposed 526 · Balance 2,000 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F8: Sale prices ranged from $176.04 to $176.88. Row 10 · 2022-04-01 · Sale · Disposed 825 · Balance 1,175 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F9: Sale prices ranged from $177.12 to $178.00. Row 11 · 2022-04-01 · Sale · Disposed 175 · Balance 1,000 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.33 · Expires 2022-06-21	Direct	0	Reported balance After 2022-04-01 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-04-01 · Exercise / conversion · Disposed 15,000 · Balance 0 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022.

F2: Sale prices ranged from $165.91 to $166.41.

F3: Sale prices ranged from $168.30 to $169.30.

F4: Sale prices ranged from $169.32 to $170.28.

F5: Sale prices ranged from $170.70 to $171.63.

F6: Sale prices ranged from $171.75 to $172.73.

F7: Sale prices ranged from $172.83 to $173.37.

F8: Sale prices ranged from $176.04 to $176.88.

F9: Sale prices ranged from $177.12 to $178.00.

ELI LILLY & Co

Report date December 31, 2009 · Filed February 03, 2010

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,000	Ending reported balance After 2009-12-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2009-12-22 · Gift · Disposed 8,553 · Balance 33,854 Row 2 · 2009-12-23 · Gift · Disposed 28,854 · Balance 5,000
Common StockSEC Table I · non-derivative	Indirectby wife	37,407	Last balance in matching sequence After 2009-12-23 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 3 · 2009-12-22 · Gift · Acquired 8,553 · Balance 8,553 F1: Reporting person disclaims beneficial ownership of these shares. Row 4 · 2009-12-23 · Gift · Acquired 28,854 · Balance 37,407 F1: Reporting person disclaims beneficial ownership of these shares.
Common StockSEC Table I · non-derivative	Indirect401(k)	909	Reported balance Holding disclosure · report date 2009-12-31 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 909
Common StockSEC Table I · non-derivative	Indirectby daughter	579	Reported balance Holding disclosure · report date 2009-12-31 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 579 F1: Reporting person disclaims beneficial ownership of these shares.

Filing footnotes · ownership attribution and instrument terms

F1: Reporting person disclaims beneficial ownership of these shares.

Rapport Therapeutics, Inc.

Report date June 10, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10	Direct	15,200	Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Sage Therapeutics, Inc.

Report date January 03, 2024 · Filed January 04, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.67 · Expires 2034-01-03	Direct	3,971	Reported balance After 2024-01-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-01-03 · Grant · Acquired 3,971 · Balance 3,971 F1: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2024 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2024, subject to the reporting person's continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2024 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2024, subject to the reporting person's continued service through such date.

Seaport Therapeutics, Inc.

Report date April 30, 2026 · Filed May 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	863,031	Reported balance After 2026-05-04 transaction · row 1 1 source row Row 1 · 2026-05-04 · Conversion · Acquired 67,031 · Balance 863,031 F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-29	Direct	12,258	Reported balance After 2026-04-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-30 · Grant · Acquired 12,258 · Balance 12,258 F2: The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-29	Direct	991,192	Reported balance After 2026-04-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-30 · Grant · Acquired 991,192 · Balance 991,192
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-04 · Conversion · Disposed 210,526 · Balance 0 F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2: The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.

Voyager Therapeutics, Inc.

Report date June 03, 2021 · Filed June 04, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.23 · Expires 2031-06-03	Direct	15,000	Reported balance After 2021-06-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-03 · Grant · Acquired 15,000 · Balance 15,000 F1: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Karuna Therapeutics, Inc.

Report date March 18, 2024 · Filed March 18, 2024

Section 16 reporting ended · disclosed 2024-03-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,550	Reported balance After 2024-03-18 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-03-18 · Disposition to issuer · Disposed 2,046 · Balance 8,550 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-03-18 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2024-03-18 · Disposition to issuer · Disposed 8,550 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F4: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.
Common StockSEC Table I · non-derivative	IndirectSteve M. Paul Family 2021 Delaware Trust	0	Reported balance After 2024-03-18 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-03-18 · Disposition to issuer · Disposed 30,304 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
Common StockSEC Table I · non-derivative	IndirectJann E Paul Revocable Trust	0	Reported balance After 2024-03-18 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2024-03-18 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
Common StockSEC Table I · non-derivative	IndirectThe Steven M Paul Revocable Trust	0	Reported balance After 2024-03-18 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2024-03-18 · Disposition to issuer · Disposed 33,882 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13.
Common StockSEC Table I · non-derivative	IndirectSteven M. Paul Family 2024 Trust	0	Reported balance After 2024-03-18 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2024-03-18 · Disposition to issuer · Disposed 30,304 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
Common StockSEC Table I · non-derivative	IndirectJann E. Paul GRAT III	0	Reported balance After 2024-03-18 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2024-03-18 · Disposition to issuer · Disposed 35,877 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.04 · Expires 2028-04-29	Direct	0	Reported balance After 2024-03-18 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-03-18 · Disposition to issuer · Disposed 136,094 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 · Expires 2028-08-08	Direct	0	Reported balance After 2024-03-18 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-03-18 · Disposition to issuer · Disposed 757,045 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2029-03-20	Direct	0	Reported balance After 2024-03-18 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-03-18 · Disposition to issuer · Disposed 449,463 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2029-03-28	Direct	0	Reported balance After 2024-03-18 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2024-03-18 · Disposition to issuer · Disposed 87,494 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2029-04-07	Direct	0	Reported balance After 2024-03-18 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2024-03-18 · Disposition to issuer · Disposed 15,205 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2019-06-26	Direct	0	Reported balance After 2024-03-18 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2024-03-18 · Disposition to issuer · Disposed 616,703 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.02 · Expires 2019-06-27	Direct	0	Reported balance After 2024-03-18 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2024-03-18 · Disposition to issuer · Disposed 71,121 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.72 · Expires 2030-02-13	Direct	0	Reported balance After 2024-03-18 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2024-03-18 · Disposition to issuer · Disposed 135,992 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $131.64 · Expires 2031-02-22	Direct	0	Reported balance After 2024-03-18 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2024-03-18 · Disposition to issuer · Disposed 161,850 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F7: These Options vested as to 25% on February 23, 2022, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $111.97 · Expires 2032-02-16	Direct	0	Reported balance After 2024-03-18 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2024-03-18 · Disposition to issuer · Disposed 146,900 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F8: These Options vested as to 25% on February 16, 2023, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $187.26 · Expires 2023-02-08	Direct	0	Reported balance After 2024-03-18 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2024-03-18 · Disposition to issuer · Disposed 22,800 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F9: These Options vested as to 25% on February 9, 2024, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.

Filing footnotes · ownership attribution and instrument terms

F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers.

F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.

F3: Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13.

F4: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.

F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.

F6: These Options are fully vested.

F7: These Options vested as to 25% on February 23, 2022, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.

F8: These Options vested as to 25% on February 16, 2023, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.

F9: These Options vested as to 25% on February 9, 2024, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 02, 2009 Filed Feb 3, 2009 23:04 UTC	ELI LILLY & Co LLY · Entity 2794	Tax withholdingCommon Stock	15,402	$36.82	$567,101.64	Disclosure SEC source: 0001209191-09-006293 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,407 Read SEC document
January 27, 2009 Filed Jan 29, 2009 22:46 UTC	ELI LILLY & Co LLY · Entity 2794	GrantRestricted Stock Unit · Derivative	51,249	$0.00	$0.00	Disclosure SEC source: 0001209191-09-005410 · doc4.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,249 Underlying: Common Stock · 51,249 shares Expires 2010-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document
October 24, 2008 Filed Feb 12, 2009 16:35 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	503	$0.00	$0.00	Disclosure SEC source: 0001209191-09-008389 · doc5.xml · nonDerivative · entry 6 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 0 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
October 24, 2008 Filed Feb 12, 2009 16:35 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	503	$0.00	$0.00	Disclosure SEC source: 0001209191-09-008389 · doc5.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,809 Read SEC document
October 10, 2008 Filed Feb 12, 2009 16:35 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	8,050	$0.00	$0.00	Disclosure SEC source: 0001209191-09-008389 · doc5.xml · nonDerivative · entry 5 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 503 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
October 10, 2008 Filed Feb 12, 2009 16:35 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	8,050	$0.00	$0.00	Disclosure SEC source: 0001209191-09-008389 · doc5.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,306 Read SEC document
February 11, 2008 Filed Feb 12, 2009 16:35 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	1,044	$0.00	$0.00	Disclosure SEC source: 0001209191-09-008389 · doc5.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 8,553 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
February 11, 2008 Filed Feb 12, 2009 16:35 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	1,044	$0.00	$0.00	Disclosure SEC source: 0001209191-09-008389 · doc5.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,256 Read SEC document
February 04, 2008 Filed Feb 5, 2008 20:49 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	3,500	$51.66	$180,810.00	Disclosure SEC source: 0001209191-08-007719 · doc4.xml · nonDerivative · entry 11 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,300 Read SEC document
February 04, 2008 Filed Feb 5, 2008 20:49 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	3,722	$51.65	$192,241.30	Disclosure SEC source: 0001209191-08-007719 · doc4.xml · nonDerivative · entry 10 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,800 Read SEC document
February 04, 2008 Filed Feb 5, 2008 20:49 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	100	$51.64	$5,164.00	Disclosure SEC source: 0001209191-08-007719 · doc4.xml · nonDerivative · entry 9 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,522 Read SEC document
February 04, 2008 Filed Feb 5, 2008 20:49 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	6,000	$51.62	$309,720.00	Disclosure SEC source: 0001209191-08-007719 · doc4.xml · nonDerivative · entry 8 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,622 Read SEC document
February 04, 2008 Filed Feb 5, 2008 20:49 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	200	$51.61	$10,322.00	Disclosure SEC source: 0001209191-08-007719 · doc4.xml · nonDerivative · entry 7 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,622 Read SEC document
February 04, 2008 Filed Feb 5, 2008 20:49 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	400	$51.56	$20,624.00	Disclosure SEC source: 0001209191-08-007719 · doc4.xml · nonDerivative · entry 6 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,822 Read SEC document
February 04, 2008 Filed Feb 5, 2008 20:49 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	2,500	$51.55	$128,875.00	Disclosure SEC source: 0001209191-08-007719 · doc4.xml · nonDerivative · entry 5 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,222 Read SEC document
February 04, 2008 Filed Feb 5, 2008 20:49 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	800	$51.54	$41,232.00	Disclosure SEC source: 0001209191-08-007719 · doc4.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,722 Read SEC document
February 04, 2008 Filed Feb 5, 2008 20:49 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	1,900	$51.50	$97,850.00	Disclosure SEC source: 0001209191-08-007719 · doc4.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,522 Read SEC document
February 04, 2008 Filed Feb 5, 2008 20:49 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	700	$51.49	$36,043.00	Disclosure SEC source: 0001209191-08-007719 · doc4.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,422 Read SEC document
February 01, 2008 Filed Feb 5, 2008 20:49 UTC	ELI LILLY & Co LLY · Entity 2794	Tax withholdingCommon Stock	11,174	$51.52	$575,684.48	Disclosure SEC source: 0001209191-08-007719 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,122 Read SEC document
January 25, 2008 Filed Jan 29, 2008 21:32 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	44,256	$50.74	$2,245,549.44	Disclosure SEC source: 0001209191-08-006241 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,296 Read SEC document
December 04, 2007 Filed Feb 12, 2008 16:53 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	1,774	$0.00	$0.00	Disclosure SEC source: 0001209191-08-009254 · doc5.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 7,509 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
December 04, 2007 Filed Feb 12, 2008 16:53 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	1,774	$0.00	$0.00	Disclosure SEC source: 0001209191-08-009254 · doc5.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,040 Read SEC document
July 31, 2007 Filed Aug 1, 2007 19:04 UTC	ELI LILLY & Co LLY · Entity 2794	OtherCommon Stock	3,163	$54.09	$171,086.67	Disclosure SEC source: 0001209191-07-044996 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) Disclosed balance after: 0 Read SEC document
June 01, 2007 Filed Jun 4, 2007 20:06 UTC	ELI LILLY & Co LLY · Entity 2794	Tax withholdingCommon Stock	1,226	$58.62	$71,868.12	Disclosure SEC source: 0001209191-07-034905 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,479 Read SEC document
May 30, 2007 Filed Feb 12, 2008 16:53 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	4,665	$0.00	$0.00	Disclosure SEC source: 0001209191-08-009254 · doc5.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 5,735 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
May 30, 2007 Filed Feb 12, 2008 16:53 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	4,665	$0.00	$0.00	Disclosure SEC source: 0001209191-08-009254 · doc5.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,040 Read SEC document
May 21, 2007 Filed May 23, 2007 19:33 UTC	ELI LILLY & Co LLY · Entity 2794	Exercise / conversionEmployee stock option 7/97 (right to buy) · Derivative	98,008	$0.00 Strike: $54.80	$0.00	Disclosure SEC source: 0001209191-07-032357 · doc4.xml · derivative · entry 6 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 98,008 shares Expires 2007-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 21, 2007 Filed May 23, 2007 19:33 UTC	ELI LILLY & Co LLY · Entity 2794	Tax withholdingCommon Stock	93,435	$59.60	$5,568,726.00	Disclosure SEC source: 0001209191-07-032357 · doc4.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,705 Read SEC document
May 21, 2007 Filed May 23, 2007 19:33 UTC	ELI LILLY & Co LLY · Entity 2794	Exercise / conversionCommon Stock	98,008	$54.80	$5,370,838.40	Disclosure SEC source: 0001209191-07-032357 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 15, 2007 Filed May 17, 2007 18:35 UTC	ELI LILLY & Co LLY · Entity 2794	Exercise / conversionEmployee stock option 7/97 (right to buy) · Derivative	1,992	$0.00 Strike: $54.80	$0.00	Disclosure SEC source: 0001209191-07-030969 · doc4.xml · derivative · entry 6 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,008 Underlying: Common Stock · 1,992 shares Expires 2007-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 15, 2007 Filed May 17, 2007 18:35 UTC	ELI LILLY & Co LLY · Entity 2794	Tax withholdingCommon Stock	1,900	$59.60	$113,240.00	Disclosure SEC source: 0001209191-07-030969 · doc4.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,132 Read SEC document
May 15, 2007 Filed May 17, 2007 18:35 UTC	ELI LILLY & Co LLY · Entity 2794	Exercise / conversionCommon Stock	1,992	$54.80	$109,161.60	Disclosure SEC source: 0001209191-07-030969 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 12, 2007 Filed Mar 13, 2007 19:05 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	7,289	$52.39	$381,870.71	Disclosure SEC source: 0001209191-07-017337 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 1,070 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person's wife on February 26, 2007. F2 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
February 12, 2007 Filed Feb 14, 2007 20:10 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	7,290	$54.38	$396,430.20	Disclosure SEC source: 0001209191-07-010452 · doc4.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 8,359 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
February 09, 2007 Filed Feb 14, 2007 20:10 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	14,579	$0.00	$0.00	Disclosure SEC source: 0001209191-07-010452 · doc4.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 15,649 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
February 09, 2007 Filed Feb 14, 2007 20:10 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	14,579	$0.00	$0.00	Disclosure SEC source: 0001209191-07-010452 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,040 Read SEC document
February 08, 2007 Filed Feb 12, 2007 15:39 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	2,700	$54.34	$146,718.00	Disclosure SEC source: 0001209191-07-009247 · doc4.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,619 Read SEC document
February 08, 2007 Filed Feb 12, 2007 15:39 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	2,000	$54.33	$108,660.00	Disclosure SEC source: 0001209191-07-009247 · doc4.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,319 Read SEC document
February 08, 2007 Filed Feb 12, 2007 15:39 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	1,600	$54.32	$86,912.00	Disclosure SEC source: 0001209191-07-009247 · doc4.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,319 Read SEC document
February 08, 2007 Filed Feb 12, 2007 15:39 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	3,792	$54.31	$205,943.52	Disclosure SEC source: 0001209191-07-009247 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,919 Read SEC document
February 01, 2007 Filed Feb 5, 2007 23:28 UTC	ELI LILLY & Co LLY · Entity 2794	Tax withholdingCommon Stock	6,985	$54.12	$378,028.20	Disclosure SEC source: 0001209191-07-007670 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,711 Read SEC document
January 17, 2007 Filed Jan 19, 2007 21:09 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	32,040	$52.86	$1,693,634.40	Disclosure SEC source: 0001209191-07-004365 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,696 Read SEC document
October 20, 2006 Filed Oct 24, 2006 15:37 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	4,836	$56.91	$275,216.76	Disclosure SEC source: 0001209191-06-055677 · doc4.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 1,070 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
September 15, 2006 Filed Sep 19, 2006 18:06 UTC	ELI LILLY & Co LLY · Entity 2794	Exercise / conversionEmployee stock option 10/96 (right to buy) · Derivative	2,890	$0.00 Strike: $34.60	$0.00	Disclosure SEC source: 0001209191-06-050738 · doc4.xml · derivative · entry 7 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,890 shares Expires 2006-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 15, 2006 Filed Sep 19, 2006 18:06 UTC	ELI LILLY & Co LLY · Entity 2794	Tax withholdingCommon Stock	1,820	$55.24	$100,536.80	Disclosure SEC source: 0001209191-06-050738 · doc4.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,726 Read SEC document
September 15, 2006 Filed Sep 19, 2006 18:06 UTC	ELI LILLY & Co LLY · Entity 2794	Exercise / conversionCommon Stock	2,890	$34.60	$99,979.55	Disclosure SEC source: 0001209191-06-050738 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 15, 2006 Filed Oct 24, 2006 15:37 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	1,070	$0.00	$0.00	Disclosure SEC source: 0001209191-06-055677 · doc4.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 5,906 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
September 15, 2006 Filed Oct 24, 2006 15:37 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	1,070	$0.00	$0.00	Disclosure SEC source: 0001209191-06-055677 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,656 Read SEC document
April 25, 2006 Filed Apr 26, 2006 17:28 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	100	$52.13	$5,213.00	Disclosure SEC source: 0001209191-06-025513 · doc4.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,656 Read SEC document
April 25, 2006 Filed Apr 26, 2006 17:28 UTC	ELI LILLY & Co LLY · Entity 2794	SaleCommon Stock	24,900	$52.06	$1,296,294.00	Disclosure SEC source: 0001209191-06-025513 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,756 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.